Abstract

In addition to being a master regulator of cell cycle progression, E2F1 regulates other associated biological processes, including growth and malignancy. Here, we uncover a regulatory network linking E2F1 to lysosomal trafficking and mTORC1 signaling that involves v-ATPase regulation. By immunofluorescence and time-lapse microscopy we found that E2F1 induces the movement of lysosomes to the cell periphery, and that this process is essential for E2F1-induced mTORC1 activation and repression of autophagy. Gain- and loss-of-function experiments reveal that E2F1 regulates v-ATPase activity and inhibition of v-ATPase activity repressed E2F1-induced lysosomal trafficking and mTORC1 activation. Immunoprecipitation experiments demonstrate that E2F1 induces the recruitment of v-ATPase to lysosomal RagB GTPase, suggesting that E2F1 regulates v-ATPase activity by enhancing the association of V0 and V1 v-ATPase complex. Analysis of v-ATPase subunit expression identified B subunit of V0 complex, ATP6V0B, as a transcriptional target of E2F1. Importantly, ATP6V0B ectopic-expression increased v-ATPase and mTORC1 activity, consistent with ATP6V0B being responsible for mediating the effects of E2F1 on both responses. Our findings on lysosomal trafficking, mTORC1 activation and autophagy suppression suggest that pharmacological intervention at the level of v-ATPase may be an efficacious avenue for the treatment of metastatic processes in tumors overexpressing E2F1.

Highlights

  • The E2F1 transcription factor is over-expressed in numerous human cancers, including lung, breast and hepatocellular carcinomas, as well as Sporadic Burkitt’sLymphomas [1,2,3,4]

  • By immunofluorescence and time-lapse microscopy we found that E2F1 induces the movement of lysosomes to the cell periphery, and that this process is essential for E2F1-induced mTORC1 activation and repression of autophagy

  • Our findings on lysosomal trafficking, mTORC1 activation and autophagy suppression suggest that pharmacological intervention at the level of v-ATPase may be an efficacious avenue for the treatment of metastatic processes in tumors overexpressing E2F1

Read more

Summary

Introduction

The E2F1 transcription factor is over-expressed in numerous human cancers, including lung, breast and hepatocellular carcinomas, as well as Sporadic Burkitt’sLymphomas [1,2,3,4]. The E2F1 transcription factor is over-expressed in numerous human cancers, including lung, breast and hepatocellular carcinomas, as well as Sporadic Burkitt’s. The E2F1 signature is strongly associated with invasive tumor progression of breast and bladder tumors [2, 5]. Activation of E2F1 is sufficient to www.impactjournals.com/oncotarget irreversibly commit cells to undergo DNA replication by transcriptional activation of a number of genes required for the G1/S transition and the coordination of mitosis [6, 7]. It is evident that other biological processes associated with proliferation and malignant transformation are regulated by E2F1, including cell growth, autophagy, invasiveness and metastasis [2, 8,9,10,11]. Despite the impact of these processes on cancer progression, the molecular mechanisms by which E2F1 regulates these responses are still unknown

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.